Jason Mast

Solid tumors have challenged CAR-T developers. This biotech raised $216 million to test a new approach statnews.com/2025/07/23/sea… via @statnews

As the FDA and Sarepta clash over what to do after the deaths of three patients from its gene therapies, parents of young children — some preparing to be dosed this summer — have been caught in between statnews.com/2025/07/24/duc…

As Sarepta, FDA tangle over Duchenne therapy, families are caught in the middle, ⁦@Jasonmmast⁩ writes statnews.com/2025/07/24/duc…

For many Duchenne families, halt to Sarepta $SRPT gene therapy treatments is heartbreak upon heartbreak statnews.com/2025/07/24/duc… My colleague @Jasonmmast with more reporting on the patient/physician perspective.

On this week's podcast: we bring on the mother of a boy with Duchenne muscular dystrophy to talk about the impact of Sarepta's gene therapy halt. w/ @adamfeuerstein, @ADeAngelis_bio statnews.com/2025/07/24/rea…

This is a fairly shocking detail in @adamfeuerstein and @Jasonmmast's latest story on why the FDA acted when it did in response to most recent $SRPT patient death:

Breaking: In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy statnews.com/2025/07/21/sar… via @statnews @adamfeuerstein @Jasonmmast

BREAKING: In surprise reversal, Sarepta $SRPT says it will pause shipments of Duchenne gene therapy statnews.com/2025/07/21/sar… via @Jasonmmast and me

The lesson of Sarepta Therapeutics vs. the FDA is clear, @matthewherper writes: In medicine, listening to critics, and responding with data, is the surest path forward. statnews.com/2025/07/21/sar…

Alarming article about overly aggressive organ procurement. I believe these cases represent a tiny fraction of organ donations but they cast a shadow on the whole effort. nytimes.com/2025/07/20/us/… via @NYTimes

Read this updated story on $srpt with comments from Peter Marks and ⁦@daphnezohar⁩ — by ⁦@adamfeuerstein⁩ and ⁦@Jasonmmast⁩ statnews.com/2025/07/18/sar…

Peter Marks, the FDA official who overruled staff to approve the drug, told STAT he agreed "it makes a fair amount of sense" to pause shipments after recent deaths. "To get a better handle on the issues before you proceed, if you decide to proceed.”

Peter Marks, the FDA official who overruled his own staff to approve Sarepta's Duchenne gene therapy, told STAT he agreed with the decision to pause shipments after recent deaths. “It does seem like it makes a fair amount of sense to get a better handle on the issues before…

We are reporting on Sarepta ( $SRPT) and the FDA's request to stop shipments of Elevidys, its gene therapy for Duchenne. If you have any tips or if you worked at the company, I'm reachable on here, by email in bio and on Signal at JasonMast.05

FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy statnews.com/2025/07/18/sar… via @statnews

Patient dies in Sarepta $SRPT gene therapy trial, adding to safety concerns statnews.com/2025/07/18/sar… via @Jasonmmast

Patient dies in Sarepta gene therapy trial, adding to safety concerns statnews.com/2025/07/18/sar…

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move, terminates work on other gene therapies We'll be doing a bit more reporting on this. I'm reachable at [email protected] and JasonMast.05 on Signal statnews.com/2025/07/16/sar…